|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Drug Hunter, Inc.
0 Patents (Medical) associated with Drug Hunter, Inc.
Journal of Medicinal Chemistry
Property-Based Drug Design Merits a Nobel Prize
Author: Hesse, Matthew J. ; Hu, Dennis X. ; Qunies, Alshaima'a M. ; Pennington, Lewis D. ; McAtee, Rory C. ; Koester, Dennis C.
Diversifying chemical space of DNA-encoded libraries: synthesis of 2-oxa-1-azaspiro(bicyclo[3.2.0])heptanes on-DNA via visible light-mediated energy transfer catalysis
Article
Author: Voight, Eric A. ; Shreiber, Scott T. ; Levitre, Guillaume ; Crane, Erika A. ; McClain, Edward J. ; Li, Longbo ; Matsuo, Bianca ; Kim, Saegun ; Molander, Gary A.
Azaspiro[3.3]heptanes are valuable synthetic targets for drug discovery programs.
100 Deals associated with Drug Hunter, Inc.
100 Translational Medicine associated with Drug Hunter, Inc.